Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy

Ингибиторы CD73-аденозинергического контрольного пути как перспективные комбинированные препараты для традиционной и передовой иммунотерапии рака
Gang Feng Guo, Huidong Shi, Roni J. Bollag, Zoya Kurago, Michael Groves, James Kenneth Byrd, Yan Ru Cui
2023-06-26

A2AR/A2BR antagonistsCD73-adenosinergic immune checkpointPD-1/PD-L1 blockadeextracellular adenosinetumor microenvironment
The cell surface enzyme CD73 is increasingly appreciated as a pivotal non-redundant immune checkpoint (IC) in addition to PD-1/PD-L1 and CTLA-4. CD73 produces extracellular adenosine (eADO), which not only inhibits antitumor T cell activity via the adenosine receptor (AR) A2AR, but also enhances the immune inhibitory function of cancer-associated fibroblasts and myeloid cells via A2BR. Preclinical studies show that inhibition of the CD73-adenosinergic pathway in experimental models of many solid tumors either as a monotherapy or, more effectively, in combination with PD-1/PD-L1 or CTLA-4 IC blockades, improves antitumor immunity and tumor control. Consequently, approximately 50 ongoing phase I/II clinical trials targeting the CD73-adenosinergic IC are currently listed on https://clinicaltrials.gov . Most of the listed trials employ CD73 inhibitors or anti-CD73 antibodies alone, in combination with A2AR antagonists, and/or with PD-1/PD-L1 blockade. Recent evidence suggests that the distribution of CD73, A2AR and A2BR in tumor microenvironments (TME) is heterogeneous, and this distribution affects CD73-adenosinergic IC function. The new insights have implications for the optimally effective, carefully tailored approaches to therapeutic targeting of this essential IC. In the mini-review, we briefly discuss the cellular and molecular mechanisms of CD73/eADO-mediated immunosuppression during tumor progression and therapy in the spatial context of the TME. We include preclinical data regarding therapeutic CD73-eADO blockade in tumor models as well as available clinical data from completed trials that targeted CD73-adenosinergic IC with or without PD-1/PD-L1 inhibitors and discuss factors that are potentially important for optimal therapeutic outcomes in cancer patients.
1
Approximately 50 phase I/II clinical trials are investigating CD73-adenosinergic checkpoint targeting, commonly using CD73 inhibitors or antibodies alone or combined with A2AR antagonists and PD-1/PD-L1 blockade.
2
CD73 functions as a non-redundant immune checkpoint by generating extracellular adenosine that suppresses antitumor T cells through A2AR and strengthens fibroblast and myeloid-cell immunosuppression through A2BR.
3
CD73, A2AR, and A2BR are heterogeneously distributed within tumor microenvironments, influencing checkpoint activity and requiring spatially tailored therapeutic strategies.
4
Preclinical inhibition of the CD73-adenosinergic pathway improves antitumor immunity and tumor control across multiple solid-tumor models, especially when combined with PD-1/PD-L1 or CTLA-4 blockade.
5
The review integrates mechanistic, preclinical, and available clinical evidence to identify factors that may determine optimal outcomes from CD73-adenosinergic checkpoint therapies.

CD73–adenosinergic immune checkpoint in the tumor microenvironment of solid tumors

Cellular and molecular mechanisms of CD73/eADO-mediated immunosuppression and the therapeutic efficacy, combinations, and spatially tailored application of CD73–adenosinergic checkpoint inhibitors

Publication Details
Publication Date
2023-06-26
Journal
Publisher
ISSN
Cited by
51
Access Type
Author Information
Authors
Gang Feng Guo
Huidong Shi
Roni J. Bollag
Zoya Kurago
Michael Groves
James Kenneth Byrd
Yan Ru Cui
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%